Gossamer Bio
SAN DIEGO, CA · Founded 2015 · CIK 0001728117 · Biotech · Public
Seralutinib, an inhaled small-molecule inhibitor targeting PDGFRα/β, CSF1R, and c-KIT for pulmonary hypertension
gossamerbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $728M
- 6 Form D · Sep 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $70,468,084 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $70,468,084 | |
| Private capital raised | Form D · SEC | $230,015,000 | |
| Private capital raised | Form D · SEC | $120,041,922 | |
| Private capital raised | Form D · SEC | $212,102,057 | |
| Private capital raised | Form D · SEC | $25,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1739 | Opprtna Therapeutics, Inc. | — | $125K |
| 1740 | IMMUNOPHOTONICS INC | — | $18M |
| 1741 | Superluminal Medicines | — | $116M |
| 1742 | Gossamer Bio | — | $728M |
| 1743 | PHI OPTICS INC | — | $450K |
| 1744 | Iambic Therapeutics | — | $323M |
| 1745 | AVT, Inc. | — | $170K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Richard Aranda, M.D.Executive Officer
- Joshua Bilenker, M.D.Director
- Kristina BurowDirector
- Laura Carter, Ph.D.Executive Officer
- Russell CoxDirector
- Thomas Daniel, M.D.Director
- Renee GalaDirector
- Bryan GiraudoExecutive Officer
- Sheila Gujrathi, M.D.Director · Executive Officer
- Faheem HasnainDirector · Executive Officer
- Jill HoweExecutive Officer
- Richard LimDirector
- Sandra Milligan, M.D., J.D.Director
- Robert NelsenDirector
- Caryn PetersonExecutive Officer
- Otello Stampacchia, Ph.D.Director
- Christian WaageExecutive Officer
- Michael YiDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.